Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate.

Sharifi R, Lee M, Ojeda L, Ray P, Stobnicki M, Guinan P

Urology1 Aug 1985Cited by 21 (Europe PMC)

PMID3927551DOI10.1016/0090-4295(85)90042-1PepBankPUB-03927551

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with Stage D2 prostate cancer, 80% in each group reported improvement in bone pain and urinary obstructive symptoms.
In plain wordsIn men with prostate cancer, bone pain and urinary symptoms improved in 80% with either leuprolide or diethylstilbestrol.
Peptide
Leuprolide
Outcome
No significant changeSubjective improvement in bone pain and urinary obstructive signs and symptoms
Study
n = 21
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Pain · Musculoskeletal
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Measurements
Subjective improvement
80%
each group; bone pain and urinary symptoms
Source sentences
Summary
Eighty per cent of patients in each group experienced subjective improvement in bone pain and urinary obstructive signs and symptoms.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755101
02HumanRandomized controlled trialEfficacy outcome
In men with Stage D2 prostate cancer, combined complete, partial and stable response percentages were greater with leuprolide than DES.
In plain wordsIn men with prostate cancer, combined complete, partial and stable response percentages were higher with leuprolide than DES.
Peptide
Leuprolide
Outcome
IncreaseComplete, partial and stable objective responses
Study
n = 21
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Tumor growth · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
Although the pooled percentages of complete, partial, and stable objective responses were greater for the leuprolide group than the DES group,
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755103
03HumanRandomized controlled trialEfficacy outcome
In men with Stage D2 prostate cancer, combined complete and partial response percentages were comparable during the reported forty-eight and sixty weeks.
In plain wordsIn men with prostate cancer, complete and partial response percentages were comparable with leuprolide and DES during the reported periods.
Peptide
Leuprolide
Outcome
No significant changeComplete and partial objective responses
Study
n = 21
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Tumor growth · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
the sums of the percentages of complete and partial objective responses were comparable for both treatment groups during the first forty-eight and sixty weeks of the study, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755104
04HumanRandomized controlled trialSafety outcome
In men with prostate cancer, vasomotor flushing occurred most often with leuprolide but required no treatment modification or discontinuation.
In plain wordsIn men with prostate cancer, flushing was more common with leuprolide than DES and required no treatment change.
Peptide
Leuprolide
Outcome
IncreaseVasomotor flushing
Study
n: not reported in source
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Adverse events · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
Vasomotor flushing, disease flare, and injection site irritation occurred most often in leuprolide patients, but did not require modification or discontinuation of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755106
05HumanRandomized controlled trialSafety outcome
In men with prostate cancer, disease flare occurred most often with leuprolide but required no treatment modification or discontinuation.
In plain wordsIn men with prostate cancer, disease flare was more common with leuprolide than DES and required no treatment change.
Peptide
Leuprolide
Outcome
IncreaseDisease flare
Study
n: not reported in source
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Adverse events · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
Vasomotor flushing, disease flare, and injection site irritation occurred most often in leuprolide patients, but did not require modification or discontinuation of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755107
06HumanRandomized controlled trialSafety outcome
In men with prostate cancer, injection site irritation occurred most often with leuprolide but required no treatment modification or discontinuation.
In plain wordsIn men with prostate cancer, injection site irritation was more common with leuprolide than DES and required no treatment change.
Peptide
Leuprolide
Outcome
IncreaseInjection site irritation
Study
n: not reported in source
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Adverse events · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
Vasomotor flushing, disease flare, and injection site irritation occurred most often in leuprolide patients, but did not require modification or discontinuation of treatment.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755108
07HumanRandomized controlled trialSafety outcome
In men with prostate cancer, serious adverse reactions were less common with leuprolide than DES.
In plain wordsIn men with prostate cancer, serious adverse reactions were less common with leuprolide than DES.
Peptide
Leuprolide
Outcome
DecreaseSerious adverse reactions
Study
n: not reported in source
Comparator
Diethylstilbestrol 3 mg per day
Outcome group
Adverse events · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
Serious adverse reactions were more common in the DES group and included fatal myocardial infarction, arrhythmia, deep venous thrombosis, and gynecomastia.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755109
08HumanNon-randomized trialEfficacy outcome
In men with prostate cancer who did not respond to DES, crossover to leuprolide generally provided no benefit.
In plain wordsIn men who did not respond to DES, subsequent leuprolide generally provided no benefit.
Peptide
Leuprolide
Outcome
Direction not reportedResponse after crossover to leuprolide
Study
n: not reported in source
Outcome group
Tumor growth · Cancer
Studied dose
1 mg per day · subcutaneousAs given in this study (human).
Source sentences
Summary
In addition, patients not responding to leuprolide generally experienced no benefit with crossover to DES, and vice versa.
1 context sentence(design, population, supporting numbers)
Summary · context
In a controlled, prospective, randomized clinical trial, we evaluated the safety and efficacy of leuprolide, a superactive analog of luteinizing hormone releasing hormone, given in a single subcutaneous injection dose of 1 mg per day, versus diethylstilbestrol (DES) 3 mg per day by mouth in patients…
Report a problemFND-0392755105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.